Sagimet Biosciences Inc
NASDAQ:SGMT

Watchlist Manager
Sagimet Biosciences Inc Logo
Sagimet Biosciences Inc
NASDAQ:SGMT
Watchlist
Price: 4.76 USD 5.78% Market Closed
Market Cap: 144.7m USD
Have any thoughts about
Sagimet Biosciences Inc?
Write Note

Sagimet Biosciences Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sagimet Biosciences Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Sagimet Biosciences Inc
NASDAQ:SGMT
Cash from Operating Activities
-$23.8m
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Sagimet Biosciences Inc
Glance View

Market Cap
153.2m USD
Industry
Biotechnology

Sagimet Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2023-07-14. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). In addition to NASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase II clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

SGMT Intrinsic Value
3.12 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Sagimet Biosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-23.8m USD

Based on the financial report for Dec 31, 2023, Sagimet Biosciences Inc's Cash from Operating Activities amounts to -23.8m USD.

What is Sagimet Biosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-32%

Over the last year, the Cash from Operating Activities growth was 3%. The average annual Cash from Operating Activities growth rates for Sagimet Biosciences Inc have been -32% over the past three years .

Back to Top